Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-109467 · Präparat HOS-093201
Compared to efavirenz 600 mg Voriconazole may be
QD, coadministered with efavirenz if
Efavirenz 300 mg QD, Efavirenz Cmax ↔ the voriconazole maintenance
coadministered with Efavirenz AUC 17% dose is increased to 400 mg BID
voriconazole 400 mg BID* and the efavirenz dose is
Compared to voriconazole 200 mg decreased to 300 mg QD. When
BID, voriconazole treatment is
Voriconazole Cmax 23% stopped, the initial dose of
efavirenz should be restored (see
Voriconazole AUC 7%
sections 4.2 and 4.4).
Other Non-Nucleoside Reverse Not studied clinically. In vitro Careful monitoring for any
Transcriptase Inhibitors studies show that the metabolism occurrence of drug toxicity
(NNRTIs) (including but not of voriconazole may be inhibited and/or lack of efficacy, and dose
limited to: delavirdine, by NNRTIs and voriconazole may adjustment may be needed.
nevirapine)* inhibit the metabolism of NNRTIs.
[CYP3A4 substrates, inhibitors The findings of the effect of
or CYP450 inducers] efavirenz on voriconazole suggest
that the metabolism of
voriconazole may be induced by an
NNRTI.
Antipsychotics
Lurasidone Although not studied, Contraindicated (see section
[CYP3A4 substrate] voriconazole is likely to 4.3)
significantly increase the plasma
concentrations of lurasidone.
Pimozide Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of pimozide 4.3)
can lead to QTc prolongation and
rare occurrences of torsades de
pointes.
Anti virals
Letermovir Voriconazole Cmax ↓ 39% If concomitant administration of
[CYP2C9 and CYP2C19 Voriconazole AUC0-12 ↓ 44% voriconazole with letermovir
inducer] Voriconazole C12 ↓ 51% cannot be avoided, monitor for
loss of voriconazole
effectiveness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): letermovir (HOS-090621) lead (HOS-085592) pimozide (HOS-085600) efavirenz (HOS-087947) delavirdine (HOS-109468) nevirapine (HOS-088064) lurasidone (HOS-086148)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 957852e12198adcc215ffd8a30cb7e945437f4ac63b363183c5c3670248e1fc0 · Zeichen 17226–19995 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 45–46
HOS-109544 · Präparat HOS-093201
45
Other Non-Nucleoside Reverse Not studied clinically. In vitro Careful monitoring for any
Transcriptase Inhibitors studies show that the metabolism occurrence of drug toxicity
(NNRTIs) (including but not of voriconazole may be inhibited and/or lack of efficacy, and dose
limited to: delavirdine, by NNRTIs and voriconazole may adjustment may be needed.
nevirapine)* inhibit the metabolism of NNRTIs.
[CYP3A4 substrates, inhibitors The findings of the effect of
or CYP450 inducers] efavirenz on voriconazole suggest
that the metabolism of
voriconazole may be induced by an
NNRTI.
Antipsychotics
Lurasidone Although not studied, Contraindicated (see section
[CYP3A4 substrate] voriconazole is likely to 4.3)
significantly increase the plasma
concentrations of lurasidone.
Pimozide Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of pimozide 4.3)
can lead to QTc prolongation and
rare occurrences of torsades de
pointes.
Anti virals
Letermovir Voriconazole Cmax ↓ 39% If concomitant administration of
[CYP2C9 and CYP2C19 Voriconazole AUC0-12 ↓ 44% voriconazole with letermovir
inducer] Voriconazole C12 ↓ 51% cannot be avoided, monitor for
loss of voriconazole
effectiveness.
Benzodiazepines
[CYP3A4 substrates] Dose reduction of
Midazolam (0.05 mg/kg IV In an independent published study, benzodiazepines should be
single dose) Midazolam AUC0- 3.7-fold considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): letermovir (HOS-090621) lead (HOS-085592) pimozide (HOS-085600) efavirenz (HOS-087947) delavirdine (HOS-109468) nevirapine (HOS-088064) lurasidone (HOS-086148) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage ef43a168f9ab76fd2a9647a23dc50db8759604cb80a4b6eb2684eff57e70dd70 · Zeichen 18658–20764 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 78
HOS-109609 · Präparat HOS-093201
Voriconazole may be
Compared to efavirenz 600 mg coadministered with efavirenz if
Efavirenz 300 mg QD, QD, the voriconazole maintenance
coadministered with Efavirenz Cmax ↔ dose is increased to 400 mg BID
voriconazole 400 mg BID* Efavirenz AUC 17% and the efavirenz dose is
decreased to 300 mg QD. When
Compared to voriconazole 200 mg voriconazole treatment is
BID, stopped, the initial dose of
Voriconazole Cmax 23% efavirenz should be restored (see
sections 4.2 and 4.4).
Voriconazole AUC 7%
Other Non-Nucleoside Reverse Not studied clinically. In vitro Careful monitoring for any
Transcriptase Inhibitors studies show that the metabolism occurrence of drug toxicity
(NNRTIs) (including but not of voriconazole may be inhibited and/or lack of efficacy, and dose
limited to: delavirdine, by NNRTIs and voriconazole may adjustment may be needed.
nevirapine)* inhibit the metabolism of NNRTIs.
[CYP3A4 substrates, inhibitors The findings of the effect of
or CYP450 inducers] efavirenz on voriconazole suggest
that the metabolism of
voriconazole may be induced by an
NNRTI.
Antipsychotics
Lurasidone Although not studied, Contraindicated (see section
[CYP3A4 substrate] voriconazole is likely to 4.3)
significantly increase the plasma
concentrations of lurasidone.
Pimozide Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of pimozide 4.3)
can lead to QTc prolongation and
rare occurrences of torsades de
pointes.
Anti virals
Letermovir Voriconazole Cmax ↓ 39% If concomitant administration of
[CYP2C9 and CYP2C19 Voriconazole AUC0-12 ↓ 44% voriconazole with letermovir
inducer] Voriconazole C12 ↓ 51% cannot be avoided, monitor for
loss of voriconazole
effectiveness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): letermovir (HOS-090621) lead (HOS-085592) pimozide (HOS-085600) efavirenz (HOS-087947) delavirdine (HOS-109468) nevirapine (HOS-088064) lurasidone (HOS-086148)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage c70898b80fc99d5c7ad2c1cde8f7ced3883c2049c59d6e28694b98f03f2f260e · Zeichen 17288–20027 im Abschnitt
Wechselwirkungen · Edurant
EDURANT 25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5–6
HOS-213931 · Präparat HOS-155234
5
Table 1: INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL
PRODUCTS
Medicinal products by Interaction Recommendations concerning
therapeutic areas Geometric mean change (%) co-administration
ANTI-INFECTIVES
Antiretrovirals
HIV NRTIs/N[t]RTIs
Didanosine*# didanosine AUC ↑ 12% No dose adjustment is required.
400 mg once daily didanosine Cmin NA Didanosine should be administered at
didanosine Cmax ↔ least two hours before or at least four
rilpivirine AUC ↔ hours after rilpivirine.
rilpivirine Cmin ↔
rilpivirine Cmax ↔
Tenofovir disoproxil *# tenofovir AUC ↑ 23% No dose adjustment is required.
245 mg once daily tenofovir Cmin ↑ 24%
tenofovir Cmax ↑ 19%
rilpivirine AUC ↔
rilpivirine Cmin ↔
rilpivirine Cmax ↔
Other NRTIs Not studied. No clinically relevant No dose adjustment is required.
(abacavir, emtricitabine, drug-drug interactions are expected.
lamivudine, stavudine
and zidovudine)
HIV NNRTIs
NNRTIs Not studied. It is not recommended to
(delavirdine, efavirenz, co-administer rilpivirine with other
etravirine, nevirapine) NNRTIs.
HIV PIs – with co-administration of low dose ritonavir
Darunavir/ritonavir*# darunavir AUC ↔ Concomitant use of rilpivirine with
800/100 mg once daily darunavir Cmin ↓ 11% ritonavir-boosted PIs causes an
darunavir Cmax ↔ increase in the plasma concentrations
rilpivirine AUC ↑ 130% of rilpivirine, but no dose adjustment
rilpivirine Cmin ↑ 178% is required.
rilpivirine Cmax ↑ 79%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) stavudine (HOS-088080) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) lamivudine (HOS-085829) didanosine (HOS-085836) zidovudine (HOS-085837) darunavir (HOS-086181) efavirenz (HOS-087947) delavirdine (HOS-109468) nevirapine (HOS-088064) ritonavir (HOS-084521) abacavir (HOS-088077) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage e6d1aeb7ba2f265a48a0f9e4bedfdb523c00ec0b8a0eab1f7f1643ca7f5bebb4 · Zeichen 2025–4372 im Abschnitt
Wechselwirkungen · Edurant
EDURANT 2.5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-213998 · Präparat HOS-155234
Table 2: INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL
PRODUCTS
Medicinal products by Interaction Recommendations concerning
therapeutic areas Geometric mean change (%) co-administration
ANTI-INFECTIVES
Antiretrovirals
HIV NRTIs/N[t]RTIs
Didanosine*# didanosine AUC ↑ 12% No dose adjustment is required.
400 mg once daily didanosine Cmin NA Didanosine should be administered at
didanosine Cmax ↔ least two hours before or at least four
rilpivirine AUC ↔ hours after rilpivirine.
rilpivirine Cmin ↔
rilpivirine Cmax ↔
Tenofovir disoproxil *# tenofovir AUC ↑ 23% No dose adjustment is required.
245 mg once daily tenofovir Cmin ↑ 24%
tenofovir Cmax ↑ 19%
rilpivirine AUC ↔
rilpivirine Cmin ↔
rilpivirine Cmax ↔
Other NRTIs Not studied. No clinically relevant No dose adjustment is required.
(abacavir, emtricitabine, drug-drug interactions are expected.
lamivudine, stavudine
and zidovudine)
HIV NNRTIs
NNRTIs Not studied. It is not recommended to
(delavirdine, efavirenz, co-administer rilpivirine with other
etravirine, nevirapine) NNRTIs.
HIV PIs – with co-administration of low dose ritonavir
Darunavir/ritonavir*# darunavir AUC ↔ Concomitant use of rilpivirine with
800/100 mg once daily darunavir Cmin ↓ 11% ritonavir-boosted PIs causes an
darunavir Cmax ↔ increase in the plasma concentrations
rilpivirine AUC ↑ 130% of rilpivirine, but no dose adjustment
rilpivirine Cmin ↑ 178% is required.
rilpivirine Cmax ↑ 79%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) stavudine (HOS-088080) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) lamivudine (HOS-085829) didanosine (HOS-085836) zidovudine (HOS-085837) darunavir (HOS-086181) efavirenz (HOS-087947) delavirdine (HOS-109468) nevirapine (HOS-088064) ritonavir (HOS-084521) abacavir (HOS-088077) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage f8d4cdaee0bf44e65f98cc6e120db4b6262a184b4f650e2f7b5c77fb0d2e65b4 · Zeichen 2027–4403 im Abschnitt
Wechselwirkungen · Voriconazole Hikma (previously Voriconazole Hospira)
Voriconazole Hikma 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 14–15
HOS-130954 · Präparat HOS-096981
14
Other Non-Nucleoside Reverse Not studied clinically. In vitro Careful monitoring for any
Transcriptase Inhibitors studies show that the metabolism occurrence of drug toxicity
(NNRTIs) (including but not of voriconazole may be inhibited and/or lack of efficacy, and dose
limited to: delavirdine, by NNRTIs and voriconazole may adjustment may be needed.
nevirapine)* inhibit the metabolism of NNRTIs.
[CYP3A4 substrates, inhibitors The findings of the effect of
or CYP450 inducers] efavirenz on voriconazole suggest
that the metabolism of
voriconazole may be induced by an
NNRTI.
Antipsychotics
Lurasidone Although not studied, Contraindicated (see section
[CYP3A4 substrate] voriconazole is likely to 4.3)
significantly increase the plasma
concentrations of lurasidone.
Pimozide Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of pimozide 4.3)
can lead to QTc prolongation and
rare occurrences of torsades de
pointes.
Anti virals
Letermovir Voriconazole Cmax ↓ 39% If concomitant administration of
[CYP2C9 and CYP2C19 Voriconazole AUC0-12 ↓ 44% voriconazole with letermovir
inducer] Voriconazole C12 ↓ 51% cannot be avoided, monitor for
loss of voriconazole
effectiveness.
Benzodiazepines
[CYP3A4 substrates] Dose reduction of
Midazolam (0.05 mg/kg IV In an independent published study, benzodiazepines should be
single dose) Midazolam AUC0-∞ ↑ 3.7-fold considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): letermovir (HOS-090621) lead (HOS-085592) pimozide (HOS-085600) efavirenz (HOS-087947) delavirdine (HOS-109468) nevirapine (HOS-088064) lurasidone (HOS-086148) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-23T14:40:00Z · SHA-256 8f5a567ef9a1f0f0bee27abd2100fc7726dcc5281b72b1f33957fd6bcec22b38 · Passage b55557a41b807282c42b6b0740a51973286f9616c5d8291c983f48be787eede8 · Zeichen 18444–20550 im Abschnitt
Wechselwirkungen · Cotellic
Cotellic 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-133156 · Präparat HOS-097388
Caution should be exercised if cobimetinib is co-administered with moderate CYP3A inhibitors.
Moderate CYP3A inhibitors include, but are not limited to, amiodarone, erythromycin, fluconazole,
miconazole, diltiazem, verapamil, delavirdine, amprenavir, fosamprenavir, imatinib. When
cobimetinib is co-administered with a moderate CYP3A inhibitor, patients should be carefully
monitored for safety.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) imatinib (HOS-110212) fluconazole (HOS-087945) erythromycin (HOS-084514) amprenavir (HOS-086183) delavirdine (HOS-109468) fosamprenavir (HOS-086182) amiodarone (HOS-085596) miconazole (HOS-115630) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-24T11:11:11Z · SHA-256 f1f2b0f1a6369a0b0850f74c6ba5e720545731feab9d3f2f0d55fff6ff804055 · Passage a718ab26290fcd6da0ef515aa02b37548d9755a8a03faf6324253d128a4bbe66 · Zeichen 1000–1395 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.